Recent laboratory research reveals that a chemical compound known for inducing psychedelic effects reduces the motivation to consume cocaine in animal models. The findings suggest that targeting specific serotonin receptors in the brain could offer a novel biological approach to treating stimulant use disorders. The study detailing these outcomes was published in the journal Psychopharmacology.
Cocaine use continues to present a massive public health challenge across the globe. Millions of individuals struggle with stimulant addiction every year, and overdose fatalities involving the drug have trended steadily upward over the past decade. Traditional medical interventions and behavioral therapies have largely struggled to help individuals maintain long-term abstinence. Cocaine produces its highly addictive profile by infiltrating and altering communication within the brain’s reward centers. It physically blocks the normal recycling process of dopamine, a chemical messenger heavily involved in anticipating and experiencing pleasure.
Normally, brain cells release dopamine to signal that something good has happened, and then quickly vacuum it back up to reset the system. By jamming this biological vacuum system, cocaine creates an unnatural flood of dopamine. This flooding occurs specifically within the meso-corticolimbic circuitry, a network of brain regions that governs how living creatures learn to seek out rewards and find the motivation to survive. Over time, this intense chemical stimulation fundamentally rewires the brain, making it increasingly difficult for a person to feel motivated by anything other than the drug.
While dopamine receives the vast majority of attention in addiction literature, cocaine also substantially increases the brain’s levels of serotonin. Serotonin is a separate chemical messenger best known for regulating mood, sleep, and sensory perception. Investigators at the University of Texas Medical Branch suspected that a specific cellular landing pad for serotonin, known as the serotonin 2A receptor, might help dictate the brain’s overriding addiction mechanics. Leah Salinsky and Christina Merritt led a research team to investigate whether activating this exact receptor could alter how much cocaine animals would willingly self-administer.
To test this hypothesis, the researchers used a laboratory compound named (-)-DOI. While not regularly encountered outside of research settings, (-)-DOI belongs to a broad class of drugs known as hallucinogens or psychedelics. Like classical psychedelics such as LSD and psilocybin, the compound produces its main behavioral effects by strongly binding to and activating the serotonin 2A receptor in the brain. Unlike those classical drugs, (-)-DOI is highly selective. It primarily interacts with this single receptor subtype without strongly stimulating the numerous other serotonin receptors scattered throughout the nervous system.
This extreme chemical precision makes the compound an ideal tool for scientists trying to isolate biological mechanisms. If a highly selective compound changes a specific behavior, researchers can be relatively confident that the target receptor is directly responsible for the shift. To ensure the validity of their tests, the team also utilized a second specialized chemical that acts as an antagonist. This second chemical acts like a cellular shield, sitting on the serotonin 2A receptor and preventing any other drugs from activating it.
The team began the experimental phase by training adult male rats to self-administer cocaine over several weeks. The animals were placed in specialized soundproof enclosures equipped with a small metal lever. When the rats pressed the lever a set number of times, a mechanized pump delivered a highly controlled amount of cocaine directly into their bloodstream. Once the rats learned this relationship and began pressing the lever at a highly consistent rate, the researchers introduced the psychedelic compound into the daily routine. They injected the rats with varying, controlled doses of (-)-DOI shortly before placing them back into the testing chambers.
The experimental results showed a steep decline in cocaine consumption after the rats received the psychedelic compound. Across all the tested doses, the animals pressed the active lever far fewer times and subsequently delivered much less cocaine to themselves compared to when they received a neutral saline solution. To ensure the rats were not simply too sedated to move, the researchers tracked how often the animals pressed a secondary dummy lever that provided no drug. The rate at which the rats pressed the inactive dummy lever remained completely unchanged. The animals also approached the active lever just as quickly as usual initially, indicating that their basic physical coordination and alertness were intact.
The researchers then completely verified the biological pathway. They conducted another round of testing where they treated the animals with the receptor-blocking agent prior to administering the highest dose of the psychedelic. When the rats received this blocking agent first, their rate of cocaine consumption rebounded. The blocking agent largely muted the suppressive effect of the psychedelic, establishing that the serotonin 2A receptor is the primary gateway through which the drug curtails immediate reward-seeking behavior.
For their next experiment, the researchers utilized a testing framework drawn from the principles of behavioral economics. This analytical approach measures a subject’s absolute motivation to obtain a reward by steadily increasing the physical effort required to get it. Humans experience this concept intuitively: someone might buy a cup of coffee every day if it costs two dollars, but they will likely stop buying it entirely if the price jumps to twenty dollars. In this rodent trial, the rats initially earned a large, satisfying dose of cocaine for just a few lever presses.
As the session progressed, the volume of cocaine delivered with each successful lever press steadily shrank at scheduled intervals. To maintain the same level of intoxication, the animals had to press the lever at intensely high, escalating rates. By the final block of the testing session, the rats had to expend an immense amount of physical effort to receive barely a fraction of the starting drug dosage. This procedure effectively estimates the absolute maximum price an animal is willing to pay before giving up completely.
This economic analysis tracks a metric known as demand elasticity, which describes just how sensitive a subject behaves when facing price hikes. The researchers found that the highest administered dose of the psychedelic compound left the rats dramatically more sensitive to the rising cost of the stimulant. When treated with the highest dose of (-)-DOI, the animals gave up much sooner as the required lever presses rapidly multiplied. Their overarching motivation to work for the stimulant eroded. The total overall amount of cocaine they managed to consume during the demanding session also dropped immensely compared to their untreated baseline behavior.
Just as in the simplest trials, administering the receptor-blocking agent before the psychedelic reversed these sweeping behavioral changes. The rats treated with the blocker returned to working incredibly hard for shrinking amounts of cocaine. This data confirmed again that turning on the serotonin 2A receptor specifically devalues the perceived, essential reward of the stimulant. The psychedelic essentially caused the cocaine to lose its overpowering appeal once the physical price of obtaining it became excessively high.
The investigators highlighted several basic boundaries to their current findings. The study exclusively observed male rats, creating a gap in understanding how female biology might alter or amplify these outcomes. Fluctuations in ovarian hormones are widely reported to influence how the brain responds to cocaine. Future laboratory trials must include female animal models to provide the complete biological picture required for medical science.
The research team also pointed out that their complex economic demand tests required delivering very high initial bursts of cocaine at the start of the session. The sheer volume of this early drug exposure might temporarily change how the entire serotonin system physically functions compared to continuous low-dose use. Future research efforts will need to test these psychedelic compounds against different ingestion patterns and observe if the effects hold steady. Scientists must also determine if activating these receptors specifically alters basic sensory perception during drug taking.
These laboratory findings arrive precisely as massive medical institutions are conducting early human trials using classical psychedelics for substance use issues. By pinpointing the exact cellular receptors that reduce drug consumption, researchers hope to guide the creation of highly specialized new medications. Ongoing medicinal chemistry projects are currently attempting to design novel drugs that can activate the serotonin 2A receptor to squelch cravings without causing the intense hallucinogenic side effects normally associated with psychedelics.
The study, “The psychedelic (−)‑2,5‑dimethoxy‑4‑iodoamphetamine [(−)‑DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats,” was authored by Leah M. Salinsky, Christina R. Merritt, Erik J. Garcia, Robert G. Fox, Joshua C. Zamora, Noelle C. Anastasio, and Kathryn A. Cunningham.